Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of OCU500 (ChAd36 Vector Encoding SARS-CoV-2 Spike) in Previously Vaccinated Adults
NCT07536308Phase 1Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2026
- Primary completion
- Apr 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of iNCOVACC in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Occurrence of abnormal clinical safety laboratory adverse events at Day 8, Occurrence of adverse events of special interest at 6 months and 6 more. Started May 2026; status: recruiting.
02
Drugs
iNCOVACC
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07536308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07536308.